Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial

西洛他唑 医学 氯吡格雷 阿司匹林 随机对照试验 内科学 抗血小板药物 临床终点 血小板聚集抑制剂 冲程(发动机) 血小板 噻氯匹定 替卡格雷 抗血栓 麻醉 工程类 机械工程
作者
Haruhiko Hoshino,Kazunori Toyoda,Katsuhiro Omae,Noriyuki Ishida,Shinichiro Uchiyama,Kazumi Kimura,Nobuyuki Sakai,Yasushi Okada,Kortaro Tanaka,Hideki Origasa,Hiroaki Naritomi,Kiyohiro Houkin,Keiji Yamaguchi,Masanori Isobe,Kazuo Minematsu,Masayasu Matsumoto,Teiji Tominaga,Hidekazu Tomimoto,Yasuo Terayama,Satoshi Yasuda,Takenori Yamaguchi
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:52 (11): 3430-3439 被引量:8
标识
DOI:10.1161/strokeaha.121.034378
摘要

Although dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the recurrence of ischemic stroke while significantly increasing the bleeding events compared with monotherapy, the CSPS.com trial (Cilostazol Stroke Prevention Study combination) showed that DAPT using cilostazol was more effective without the bleeding risk. In the CSPS.com trial, aspirin or clopidogrel was used as the underlying antiplatelet drug. The effectiveness and safety of each combination were examined and clarified.In the CSPS.com trial, a multicenter, open-label, randomized controlled study, patients with high-risk, noncardioembolic ischemic stroke 8 to 180 days after onset treated with aspirin or clopidogrel alone at the discretion of the physician in charge were recruited. Patients were randomly assigned to receive either monotherapy or DAPT using cilostazol and followed for 0.5 to 3.5 years. The primary efficacy outcome was first recurrence of ischemic stroke. The safety outcome was severe or life-threatening bleeding. The analysis was based on the underlying antiplatelet agents.A total of 763 patients taking aspirin and 1116 taking clopidogrel were included in the intention-to-treat analysis. Although the clopidogrel group had more risk factors than the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the 2 groups. In the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the DAPT group and the aspirin-monotherapy group. In the clopidogrel group, the primary end point occurred at a rate of 2.31 per 100 patient-years in the DAPT group and 5.19 per 100 patient-years in the clopidogrel-monotherapy group (hazard ratio, 0.447 [95% CI, 0.258–0.774]). Safety outcome did not differ significantly between groups (0.51 per 100 patient-years versus 0.71 per 100 patient-years, respectively; hazard ratio, 0.730 [95% CI, 0.206–2.588]).The combination of cilostazol and clopidogrel significantly reduced the recurrence of ischemic stroke without increasing the bleeding risk in noncardioembolic, high-risk patients.URL: https://www.clinicaltrials.gov; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000012180.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dinglingling发布了新的文献求助10
1秒前
亮总完成签到 ,获得积分10
1秒前
TANG发布了新的文献求助10
2秒前
firefly00001发布了新的文献求助10
2秒前
zlhzs关注了科研通微信公众号
3秒前
铱铱的胡萝卜完成签到,获得积分10
3秒前
Tulip发布了新的文献求助10
3秒前
送你一颗流星完成签到,获得积分10
4秒前
aaaaaa发布了新的文献求助10
9秒前
尊嘟假嘟发布了新的文献求助10
14秒前
15秒前
16秒前
朴BOSS完成签到,获得积分10
16秒前
zhou完成签到,获得积分10
17秒前
ider完成签到 ,获得积分10
17秒前
叶叶叶完成签到,获得积分10
18秒前
ybk666完成签到,获得积分10
20秒前
jjj完成签到 ,获得积分10
21秒前
pzc发布了新的文献求助10
23秒前
乐乐应助swzzaf采纳,获得10
23秒前
科目三应助ZZQ采纳,获得10
24秒前
小涛涛完成签到 ,获得积分10
25秒前
一道精致的灰完成签到 ,获得积分10
28秒前
29秒前
孔令琦完成签到,获得积分10
29秒前
大脸鲤完成签到 ,获得积分10
30秒前
rx123完成签到,获得积分10
31秒前
pzc关闭了pzc文献求助
33秒前
昊昊发布了新的文献求助10
35秒前
35秒前
搜集达人应助aaaaaa采纳,获得10
36秒前
Jasper应助柚子采纳,获得10
37秒前
丘比特应助昊昊采纳,获得10
41秒前
小二郎应助rx123采纳,获得10
41秒前
41秒前
42秒前
ningqing完成签到,获得积分10
42秒前
小二郎应助高高饼干采纳,获得10
42秒前
糯米饭团完成签到 ,获得积分20
43秒前
Qiancheni完成签到,获得积分10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Periodic Report Summary 2 - AFTER (A Framework for electrical power sysTems vulnerability identification, dEfense and Restoration) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7319661
求助须知:如何正确求助?哪些是违规求助? 8935296
关于积分的说明 18941716
捐赠科研通 6978227
什么是DOI,文献DOI怎么找? 3214413
关于科研通互助平台的介绍 2382269
邀请新用户注册赠送积分活动 2193439